Hexarelin vs Tesamorelin
A side-by-side research comparison of Hexarelin and Tesamorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Hexarelin | Tesamorelin |
|---|---|---|
| Full name | Hexarelin (Examorelin) | Tesamorelin Acetate (Egrifta) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | FDA Approved |
| Mechanism | Potent GHSR-1a agonist producing maximal pituitary GH output. Additionally binds cardiac CD36, providing cardioprotection through anti-apoptotic mechanisms independent of GH. | Binds pituitary GHRH receptors with enhanced affinity via hexenoic acid modification. Effective at mobilizing visceral fat via GH-mediated lipolysis. |
| Molecular weight | 887 Da | 5,136 Da |
| Half-life | 1-2 hours | 26-38 minutes |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 100-200 mcg | 2 mg |
| Frequency | 2-3x daily | Once daily |
| Route | Subcutaneous | Subcutaneous injection |
Hexarelin reported benefits
- Strongest GH release
- Cardioprotective effects
- Recovery acceleration
- Anti-fibrotic (cardiac)
- Neuroprotective potential
Tesamorelin reported benefits
- Visceral fat reduction (up to 18%)
- FDA-approved safety
- Improved lipid panels
- Cognitive benefits (emerging)
- No significant IGF-1 overshoot
Related comparisons
Research and educational reference only. Not medical advice.